I keep looking at New York State as the indicator for what's to come in the US. For new cases/capita, it's leading the US. If it were a country, it would now be the 2nd highest in the world after Ireland. In contrast to the CDC, the state has a lot of solid new data to review /1
NYS "fully vaxx" rate is 72% and also has better than US avg for older age groups.
There's some reduction of vaccine effectiveness vs hospitalization recently, but the overwhelming proportion of patients admitted are among the unvaccinated /3
Here are the case data by vaccinated status, which shows more VE attrition than hospitalization (as expected). And the shift from Delta to Omicron dominance that just took place recently/4
I can't find any VE data for💉💉waned, 3rd shots. Putting that aside, these findings are v concerning. Omicron's impact isn't yet baked in for severe disease, but already signs of VE reduction.
NYS has a much better immunity wall than much of the US, but less than many countries
• • •
Missing some Tweet in this thread? You can try to
force a refresh
For more than a year we've been talking about Global Vaccine equity.
Now it'll also be Global Pill Equity.
Unless something is done to get production revved up, as discussed here theguardian.com/commentisfree/…
Last week @CDCgov reported Omicron was 2.9% (that has now been revised)
*Today it is 73%*
Dominant across the US (with heterogeneity)
This is a doubling growth rate of 2 days or less
Replicates what has been seen in South Africa, UK, Denmark
Last week's 2.9% of cases being Omicron has been revised upward to 12.6%
12.6% -->73% of new cases are now Omicron
That's what you call exponential growth, folks
First data on booster vaccine effectiveness vs Omicron (581 cases): drop in protection vs symptomatic infection by 2 doses (AZ ->0, Pfizer-> <40%) restored to ~75% with 3rd shot Pfizer assets.publishing.service.gov.uk/government/upl…@UKHSA
The 95% CI presented here with relatively small number of Omicron cases overlap vs Delta, but certainly suggest less protection after 3rd dose.
For Omicron, essentially no protective effect of 2 AZ doses, 3rd goes to 71% (42,86); 2 Pfizer doses to 34%, 3rd doses to 76% (56,83)
Much more new beyond 1st look at Omicron vaccine effectiveness, summarized in a terrific thread by @kallmemeg
The overwhelming evidence for 3rd shot boosters *before* Omicron, reinforced by new data for benefit vs Omicron 1. The randomized trial of 3 shots vs 2 shots + placebo, 95% efficacy for preventing symptomatic infections across all age 16+ groups (N=10,125) cdc.gov/vaccines/acip/…
3. Marked reduction of hospitalizations and deaths in over 728,321 people with 3 shots vs matched 728,321 people with 2 shots, across all age groups thelancet.com/action/showPdf…
Great credit to this team for quickly getting us Omicron lab neutralization data. The bright side is that there is incomplete immune escape from vaccination👍
For people who had Prior Covid plus vaccination, the preserved Omicron neutralization level (FRNT) likely reflects solid protection. Not seen with 2 doses of Pfizer vaccine, but would expect that a 3rd shot, with its marked effect on raising nAbs, would simulate that
Here are some relevant data for the small sample. The 6 vaccinated individuals range from 10-39 days post-vaxx.
Take home point is how powerful hybrid immunity (vaccine + prior Covid) vs all variants that we've seen now, including Omicron